A Long-term Follow-up of Study 64041575RSV2004 to Evaluate the Impact of Lumicitabine (JNJ-64041575) on the Incidence of Asthma and/or Wheezing in Infants and Children With a History of Respiratory Syncytial Virus Infection
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Dec 2018
At a glance
- Drugs Lumicitabine (Primary)
- Indications Respiratory syncytial virus infections
- Focus Therapeutic Use
- Acronyms PLUM Follow-up
- Sponsors Janssen Research & Development
- 08 Dec 2018 This trial was discontinued in Portugal.
- 04 Dec 2018 Planned End Date changed from 30 Apr 2021 to 27 Apr 2020.
- 04 Dec 2018 Planned primary completion date changed from 30 Apr 2021 to 27 Apr 2020.